Supporting Information

Supplemental Figures




Figure S1. Gating strategy for Treg/Tconv identification in SPL and TUM by flow cytometry.

Flow cytometry analysis was performed on lymphocytes extracted from single spleens (SPL) and tumors (TUM) from C57BL/6 mice bearing MCA38 nodules. (A) Sequential hierarchical gating strategy for the selection of CD4 T cells. (B) In gated CD4 T cells, Tregs and Tconvs were selected according to Foxp3 intracellular expression. *Right*, Bodipy levels in overlaid Treg/Tconv subsets.




Figure S2. Tumor-infiltrating Tregs accumulate intracellular lipids also in another tumor model (B16F10).

 10^5 B16F10 cells were injected s.c. into C57BL/6 mice, and flow cytometry analysis was performed on lymphocytes extracted from spleen (SPL) and tumor (TUM) after 14 days. (A) Representative histograms and (B) geometric mean fluorescence intensity (gMFI) analysis of Bodipy staining in gated CD25+Foxp3+ Tregs (red) and CD25-Foxp3- Tconvs (blue) in SPL (empty peaks and bars) and TUM (solid peaks and bars) from tumor-bearing mice. Peaks in grey represent the fluorescence-minus-one (FMO) controls. (C) Ratio between Bodipy gMFI in Tregs and Tconvs from SPL and TUM. Error bars show mean \pm SEM, each dot corresponds to a single mouse. Data shown are from a representative out of two independent experiments. *p < 0.05, **p < 0.01, by Student t test, paired between Tregs and Tconvs in the same samples; unpaired, between populations of different samples.




Figure S3. High intracellular lipid accumulation occurs in expanding Tregs also in the inflamed hepatic microenvironment.

(A-C) Analysis of CD25+Foxp3+ Tregs and CD25-Foxp3- Tconvs from spleen (SPL) and liver (LIV) of wild type (wt) and $Mdr2^{-/-}$ mice. (A) Frequency of Tregs in gated CD4+ lymphocytes from the indicated samples. (B) Geometric mean fluorescence intensity (gMFI) of Nile Red staining in Tregs (red) and Tconvs (blue) from spleen (empty bars) and liver (filled bars) of wt and $Mdr2^{-/-}$ mice. (C) Ratio between Nile Red gMFI in Tregs and Tconvs in spleen and liver of wt and $Mdr2^{-/-}$ mice.

(D-F) Analysis of CD25+Foxp3+ Tregs and CD25-Foxp3- Tconvs from spleen (SPL) and liver (LIV) of wild type (wt) and HCV transgenic (HCVTg) mice. (D) Frequency of Tregs in gated CD4+ lymphocytes from the indicated samples. (E) gMFI of Nile Red staining in Tregs (red) and Tconvs (blue) from spleen (empty bars) and liver (filled bars) of wt and HCVTg mice. (F) Ratio between Nile Red gMFI of Tregs and Tconvs in spleen and liver of wt and HCVTg mice.

Error bars show mean \pm SEM, *p < 0.05, **p < 0.01, by Student t test, paired between Tregs and Tconvs in the same sample; unpaired, between populations of different samples. Each dot corresponds to a single mouse; data shown are from a representative out of two independent experiments.




Figure S4. TOFA and Etx treatments mostly target tumor cells.

(A, D) Tumor-bearing mice were treated with repeated intra-tumor (i.t.) TOFA (A) or Etx (D) injections at days 5, 8, 11, 13 after MCA38 s.c. transplantation, and tumor growth was monitored. (B, E) At day 14, spleen (SPL) and tumors (TUM) were collected and tumor-infiltrating CD8 T cells characterization was performed, in terms of frequency (left panels) and IFN γ production (right panels). Data are shown as mean \pm SEM, 2-5 mice were included in each experimental group; *p < 0.05, **p < 0.01, ***p < 0.005, by Student t test, unpaired.

(C, F) MCA38 cells were cultured in vitro with the indicated TOFA (C) or Etx (F) concentrations, and XTT cytotoxicity assay was performed after 24 hours. Error bars show mean \pm SEM, data shown are representative of one out of two independent experiments. *p < 0.05, **p < 0.01, ***p < 0.005, by Student t test, unpaired.




Figure S5. TOFA exposure increases Tconv and Treg survival in vitro.

Magnetically purified Tregs and Tconvs were labelled with eFluor670 and cocultured at 1:1 ratio with feeder cells, anti-CD3 and IL-2, with or without TOFA (5 μ g/ml). After 4 days, cells were stained with the viability dye eFluor780, Bodipy, CD4 and Foxp3, and flow cytometry analysis was performed in gated Tregs (CD4+Foxp3+, red) or Tconvs (CD4+Foxp3-, blue). Numbers indicate the frequency of dead cells, evaluated as the percentage of cells labelled with the viability dye eFluor780 in each gate.

Each condition was tested in triplicates; data shown are from a representative out of two independent experiments. Error bars show mean \pm SEM, *p < 0.05, ***p < 0.005, by Student t test, unpaired.





Figure S6. TOFA-treated Tregs may display lower suppressive activity against antitumor concomitant immunity in vivo.

Tregs were isolated through immunomagnetic separation from the spleens of naïve mice, cultured in vitro 40 hours with aCD3/IL-2, in the presence of TOFA or DMSO (ctrl). Then, Tregs were co-injected at 1:1 ratio with 10⁵ MCA38 tumor cells, subcutaneously in the left flank of mice already bearing palpable MCA38-tumors on the right flank (10 days after the primary tumor inoculation); as control, tumor cells only (TUM) were injected. After further 13 days, flow cytometry analysis was performed in lymphocytes extracted from secondary tumor-draining lymph nodes (DLN) and the growing secondary tumors (2 in the group TUM, 2 in the group TUM+Treg TOFA, and only 1 in the TUM+Treg ctrl). (A) Contour plots showing the frequency of CD44hi in gated CD8 T cells, and of TNF α +/IFN γ + in gated CD8+CD44hi T cells, in DLN and TUM in each experimental group. Samples in the bottom line show the staining controls on CD8+CD44hi splenocytes; FMO, fluorescence-minus-one; BFA/MON, cultured with BFA/MON only in the absence of PMA/ionomycin. (B) Histogram overlay of IFN γ and TNF α in TUM-infiltrating gated CD8+CD44hi in the indicated groups; numbers indicate the geometric mean fluorescence intensity (gMFI).






Figure S7. Metabolomic profile of Tregs and Tconvs freshly extracted from tumor and spleens.

CD4+CD25+ Tregs and CD4+CD25- Tconvs were magnetically purified from pooled spleens and tumors of tumor-bearing mice, and metabolomic profiling was performed directly ex vivo. (A) Diagram showing the levels of each metabolite in the context of glycolysis, pentose-phosphate, and TCA cycle pathways. (B-C) Levels of analytes and parameters, indicating the redox and energy status in each condition.

Table S1

List of the 216 genes found upregulated >2 fold only in Treg CT OX40+ versus Treg PB OX40-, and not in all the other cell subsets analyzed (Treg CT OX40-, Treg PB OX40+ and all Tconvs counterparts).

	RefSeq Gene	Gene Symbol	Gene description			
1	Hs.413494					
2	Hs.534439					
3	Hs.554324					
4	Hs.564874					
5	Hs.571502					
6	NM_000093.2	COL5A1	collagen type V alpha 1 chain			
7	NM_000130.2	F5	coagulation factor V (proaccelerin, labile factor)			
8	NM_000169.1	GLA	galactosidase, alpha			
9	NM 000211.1	ITGB2	integrin, beta 2			
10	NM 000259.1	MYO5A	myosin VA (heavy chain 12, myoxin)			
11	NM 000310.2	PPT1	palmitoyl-protein thioesterase 1			
12	NM 000365.4	TPI1	triosephosphate isomerase 1			
13	NM 000474.3	TWIST1	twist family bHLH transcription factor 1			
14	NM 000521.2	HEXB	hexosaminidase B			
15	NM 000595.2	LTA	lymphotoxin alpha (TNF superfamily, member 1)			
16	NM 000616.2	CD4	CD4 molecule			
17	NM 000675.3	ADORA2A	adenosine A2a receptor			
18	NM 000877.2	IL1R1	interleukin 1 receptor, type I			
19	NM 001001870.1	C17orf91	chromosome 17 open reading frame 91			
20	NM 001017980.1	LOC203547	hypothetical protein LOC203547			
20	NM_001024912.1	CEACAM1	carcinoembryonic antigen-related cell adhesion molecule 1			
21	1001021912.1	CLATCATION	(biliary glycoprotein)			
22	NM 001033046.1	C17orf62	chromosome 17 open reading frame 62			
23	NM 001039933.1	CD79B	CD79b molecule			
24	NM 001040168.1	LFNG	LFNG O-fucosylpeptide 3-beta-N-			
		Linto	acetylglucosaminyltransferase			
25	NM_001066.2	TNFRSF1B	tumor necrosis factor receptor superfamily member 1B			
			(TNFR2)			
26	NM_001130677.1	C17ORF96	chromosome 17 open reading frame 96			
27	NM_001183.3	ATP6AP1	ATPase, H+ transporting, lysosomal accessory protein 1			
28	NM_001252.2	TNFSF7	tumor necrosis factor (ligand) superfamily, member 7 (CD70)			
29	NM 001288.4	CLIC1	chloride intracellular channel 1			
30	NM 001386.4	DPYSL2	dihydropyrimidinase-like 2			
31	NM 001398.2	ECH1	enoyl-CoA hydratase 1, peroxisomal			
32	NM 001418.3	EIF4G2	eukaryotic translation initiation factor 4 gamma, 2			
33	NM 001428.2	ENO1	enolase 1, (alpha)			
34	NM 001559.2	IL12RB2	interleukin 12 receptor subunit beta 2			
35	NM 001611.2	ACP5	acid phosphatase 5, tartrate resistant			
36	NM 001613.1	ACTA2	actin, alpha 2, smooth muscle, aorta			
37	NM 001615.3	ACTG2	actin, gamma 2, smooth muscle, aorta			
38	NM_001618.2	PARP1	poly (ADP-ribose) polymerase family, member 1			
39	NM 001659.1	ARF3	ADP-ribosylation factor 3			
40	NM 001693.2	ATP6V1B2	ATPase, H+ transporting, lysosomal 56/58kDa, V1 subunit			
			B, isoform 2			
41	NM 001759.2	CCND2	cyclin D2			
42	NM 001767.2	CD2	CD2 molecule			
42	NM 001776.3	ENTPD1	ectonucleoside triphosphate diphosphohydrolase 1 (CD39)			
43	NM 001779.1	CD58	CD58 molecule			
44	NM 001780.3	CD38 CD63	CD58 Infoecute CD63 antigen (melanoma 1 antigen)			
43	11111_001/80.3	CD03	CDOS antigen (metanoma 1 antigen)			

46	NM 001814.2	CTSC	cathepsin C			
47	NM 001852.3	COL9A2	collagen, type IX, alpha 2			
48	NM 001903.2	CTNNA1	catenin (cadherin-associated protein), alpha 1, 102kDa			
49	NM 001979.4	EPHX2	epoxide hydrolase 2, cytoplasmic			
50	NM 002046.2	GAPDH	glyceraldehyde-3-phosphate dehydrogenase			
51	NM 002064.1	GLRX	glutaredoxin (thioltransferase)			
52	NM 002076.2	GNS	glucosamine (N-acetyl)-6-sulfatase (Sanfilippo disease			
	_		IIID)			
53	NM_002080.2	GOT2	glutamic-oxaloacetic transaminase 2			
54	NM_002125.3	HLA-DRB5	major histocompatibility complex, class II, DR beta 5			
55	NM_002167.2	ID3	inhibitor of DNA binding 3, dominant negative helix-loop-			
	_		helix protein			
56	NM_002194.2	INPP1	inositol polyphosphate-1-phosphatase			
57	NM_002284.3	KRT86	keratin 86, type II			
58	NM_002298.2	LCP1	lymphocyte cytosolic protein 1 (L-plastin)			
59	NM_002305.2	LGALS1	lectin, galactoside-binding, soluble, 1 (galectin 1)			
60	NM_002351.1	SH2D1A	SH2 domain protein 1A, Duncan's disease			
			(lymphoproliferative syndrome)			
61	NM_002413.3	MGST2	microsomal glutathione S-transferase 2			
62	NM_002460.1	IRF4	interferon regulatory factor 4			
63	NM_002475.2	MLC1SA	myosin light chain 1 slow a			
64	NM_002525.1	NRD1	nardilysin (N-arginine dibasic convertase)			
65	NM_002654.3	PKM2	pyruvate kinase, muscle			
66	NM_002674.2	РМСН	pro-melanin concentrating hormone			
67	NM_002708.3	PPP1CA	protein phosphatase 1, catalytic subunit, alpha isozyme			
68	NM_002748.2	MAPK6	mitogen-activated protein kinase 6			
69	NM_002790.2	PSMA5	proteasome (prosome, macropain) subunit, alpha type, 5			
70	NM_002818.2	PSME2	proteasome activator subunit 2			
71	NM_002872.3	RAC2	ras-related C3 botulinum toxin substrate 2 (rho family,			
			small GTP binding protein Rac2)			
72	NM_002922.3	RGS1	regulator of G-protein signaling 1			
73	NM_002999.2	SDC4	syndecan 4			
74	NM_003234.1	TFRC	transferrin receptor (p90, CD71)			
75	NM_003355.2	UCP2	uncoupling protein 2 (mitochondrial, proton carrier)			
76	NM_003365.2	UQCRC1	ubiquinol-cytochrome c reductase core protein I			
77	NM_003650.2	CST7	cystatin F (leukocystatin)			
78	NM_003656.3	CAMK1	Calcium/calmodulin-dependent protein kinase I			
79	NM_003689.2	AKR7A2	aldo-keto reductase family 7, member A2 (aflatoxin			
80	NM 002745 1	SOCSI	aldehyde reductase) suppressor of cytokine signaling 1			
80	NM_003745.1 NM_003746.1	SOCS1 DNCL1	dynein, cytoplasmic, light polypeptide 1			
81 82	NM 003805.3	CRADD	CASP2 and RIPK1 domain containing adaptor with death			
02	11111_003003.3	CRADD	domain			
83	NM 003855.2	IL18R1	interleukin 18 receptor 1			
84	NM 003884.4	KAT2B	K(lysine) acetyltransferase 2B			
85	NM 003975.2	SH2D2A	SH2 domain protein 2A			
86	NM 003978.2	PSTPIP1	proline-serine-threonine phosphatase interacting protein 1			
87	NM 004036.2	ADCY3	adenylate cyclase 3			
88	NM 004040.2	RHOB	ras homolog family member B			
89	NM 004120.3	GBP2	guanylate binding protein 2, interferon-inducible			
90	NM 004124.2	GMFB	glia maturation factor, beta			
91	NM 004225.1	MFHAS1	malignant fibrous histiocytoma amplified sequence 1			
92	NM 004251.3	RAB9A	RAB9A, member RAS oncogene family			
93	NM 004355.2	CD74	CD74 molecule, major histocompatibility complex, class II			
			invariant chain			
94	NM_004364.2	CEBPA	CCAAT/enhancer binding protein (C/EBP), alpha			
95	NM_004642.2	CDK2AP1	cyclin-dependent kinase 2 associated protein 1			
96	NM_004910.1	PITPNM1	phosphatidylinositol transfer protein, membrane-associated			
	. —		· · · · · · · · · · · · · · · · · · ·			

			1			
97	NM 004926.2	ZFP36L1	zinc finger protein 36, C3H type-like 1			
98	NM 005063.4	SCD	stearoyl-CoA desaturase (delta-9-desaturase)			
99	NM_005177.2	ATP6V0A1	ATPase, H+ transporting, lysosomal V0 subunit a isoform 1			
100	NM_005348.2	HSP90AA1	heat shock protein 90kDa alpha (cytosolic), class A member 1			
101	NM_005384.2	NFIL3	nuclear factor, interleukin 3 regulated			
102	NM_005415.3	SLC20A1	solute carrier family 20 (phosphate transporter), member 1			
103	NM_005436.2	CCDC6	coiled-coil domain containing 6			
104	NM_005532.3	IFI27	interferon, alpha-inducible protein 27			
105	NM_005533.2	IFI35	interferon-induced protein 35			
106	NM_005755.2	EBI3	Epstein-Barr virus induced 3			
107	NM_005937.2	MLLT6	myeloid/lymphoid or mixed-lineage leukemia			
108	NM_005966.3	NAB1	NGFI-A binding protein 1			
109	NM_006007.1	ZFAND5	zinc finger, AN1-type domain 5			
110	NM_006110.1	CD2BP2	CD2 (cytoplasmic tail) binding protein 2			
111	NM_006120.2	HLA-DMA	major histocompatibility complex, class II, DM alpha			
112	NM_006137.6 NM_006407.3	CD7	CD7 molecule			
113	-	ARL6IP5	ADP ribosylation factor like GTPase 6 interacting protein 5			
114 115	NM_006556.2 NM_006564.1	PMVK CXCR6	phosphomevalonate kinase chemokine (C-X-C motif) receptor 6			
115	NM 006759.3	UGP2	UDP-glucose pyrophosphorylase 2			
117	NM 006824.1	EBNA1BP2	EBNA1 binding protein 2			
118	NM 006869.1	CENTA1	centaurin, alpha 1			
119	NM 007063.2	TBC1D8	TBC1 domain family, member 8 (with GRAM domain)			
120	NM 007200.3	AKAP13	kinase (PRKA) anchor protein 13			
121	NM 007254.2	PNKP	polynucleotide kinase 3'-phosphatase			
122	NM 012428.1	SDFR1	stromal cell derived factor receptor 1			
123	NM 014038.1	BZW2	basic leucine zipper and W2 domains 2			
124	NM 014061.3	MAGEH1	melanoma antigen family H, 1			
125	NM_014142.2	NUDT5	nudix hydrolase 5			
126	NM_014241.2	PTPLA	protein tyrosine phosphatase-like (proline instead of catalytic arginine), member a			
127	NM_014380.1	NGFRAP1	nerve growth factor receptor (TNFRSF16) associated protein 1			
128	NM 014383.1	ZBTB32	zinc finger and BTB domain containing 32			
129	NM_014508.2	APOBEC3C	apolipoprotein B mRNA editing enzyme, catalytic polypeptide-like 3C			
130	NM 014583.2	LMCD1	LIM and cysteine-rich domains 1			
131	NM_014661.3	FAM53B	family with sequence similarity 53 member B			
132	NM_014832.1	TBC1D4	TBC1 domain family, member 4			
133	NM_015124.2	GRAMD4	GRAM domain containing 4			
134	NM_015150.1	RFTN1	raftlin, lipid raft linker 1			
135	NM_015187.1	KIAA0746	KIAA0746 protein			
136	NM_015404.1	DFNB31	deafness, autosomal recessive 31			
137	NM_015528.1	RNF167	ring finger protein 167			
138	NM_015559.1	SETBP1	SET binding protein 1			
139	NM_015994.2	ATP6V1D	ATPase, H+ transporting, lysosomal 34kDa, V1 subunit D			
140	NM_016053.1	CCDC53	coiled-coil domain containing 53			
141	NM_016086.2	STYXL1	serine/threonine/tyrosine interacting-like 1			
142	NM_016459.3	MZB1	marginal zone B and B1 cell-specific protein			
143	NM_016497.2	MRPL51	mitochondrial ribosomal protein L51			
144 145	NM_016633.2 NM_017515.3	AHSP SLC35F2	alpha hemoglobin stabilizing protein solute carrier family 35, member F2			
143	NM 017654.2	SAMD9	sterile alpha motif domain containing 9			
140	NM 017664.2	ANKRD10	ankyrin repeat domain 10			
147	NM 017773.2	LAX1	lymphocyte transmembrane adaptor 1			
170	1111_01/1/13.4	1.1.1.1.1				

149	NM 017775.2	TTC19	tetratricopeptide repeat domain 19			
150	NM 017791.1	FLVCR2	feline leukemia virus subgroup C cellular receptor family,			
	_		member 2			
151	NM_018064.2	AKIRIN2	akirin 2			
152	NM_018129.1	PNPO	pyridoxamine 5'-phosphate oxidase			
153	NM_018407.4	LAPTM4B	lysosomal protein transmembrane 4 beta			
154	NM_018590.3	CSGALNA	chondroitin sulfate N-acetylgalactosaminyltransferase 2			
		CT2				
155	NM_018950.1	HLA-F	major histocompatibility complex, class I, F			
156	NM_019026.2	TMCO1	transmembrane and coiled-coil domains 1			
157	NM_019043.3	APBB1IP	amyloid beta (A4) precursor protein-binding, family B,			
158	NM 020441.2	CORO1B	member 1 interacting protein coronin, actin binding protein, 1B			
158	NM 020531.2	APMAP	adipocyte plasma membrane associated protein			
160	NM 021127.1	PMAIP1	phorbol-12-myristate-13-acetate-induced protein 1			
161	NM 021270.2	LAIR2	leukocyte-associated immunoglobulin-like receptor 2			
162	NM 021983.4	HLA-DRB4	major histocompatibility complex, class II, DR beta 4			
163	NM 022153.1	C100RF54	chromosome 10 open reading frame 54			
164	NM 022476.2	AKTIP	AKT interacting protein			
165	NM 022748.9	TNS3	tensin 3			
166	NM_023927.1	GRAMD3	GRAM domain containing 3			
167	NM_023933.1	FAM173A	family with sequence similarity 173, member A			
168	NM_024092.1	TMEM109	transmembrane protein 109			
169	NM_024298.2	MBOAT7	membrane bound O-acyltransferase domain containing 7			
170	NM_024508.3	ZBED2	zinc finger, BED-type containing 2			
171	NM_024928.3	OBFC1	oligonucleotide/oligosaccharide-binding fold containing 1			
172	NM_025216.2	WNT10A	wingless-type MMTV integration site family member 10A			
173	NM_025250.2	ТТҮНЗ	tweety family member 3			
174	NM_031243.1	HNRPA2B1	heterogeneous nuclear ribonucleoprotein A2/B1			
175	NM_032199.1	ARID5B	AT rich interactive domain 5B (MRF1-like)			
176	NM_032704.3	TUBA1C	tubulin, alpha 1c			
177 178	NM_032802.2	SPPL2A EPSTI1	signal peptide peptidase-like 2A epithelial stromal interaction 1 (breast)			
178	NM_033255.2 NM_052941.2	GBP4	guanylate binding protein 4			
180	NM 053041.1	COMMD7	COMM domain containing 7			
181	NM 054025.1	B3GAT1	beta-1,3-glucuronyltransferase 1 (glucuronosyltransferase			
101	1111_051025.1	DJGIII	P)			
182	NM 080816.2	SIRPG	signal-regulatory protein gamma			
183	NM 138371.1	PCED1B	PC-esterase domain containing 1B			
184	NM_138578.1	BCL2L1	BCL2-like 1			
185	NM_138801.1	GALM	galactose mutarotase (aldose 1-epimerase)			
186	NM_138821.1	PAM	peptidylglycine alpha-amidating monooxygenase			
187	NM_139266.1	STAT1	signal transducer and activator of transcription 1, 91kDa			
188	NM_144641.1	PPM1M	protein phosphatase 1M (PP2C domain containing)			
189	NM_145169.1	SFT2D1	SFT2 domain containing 1			
190	NM_152405.1	JMY	junction-mediating and regulatory protein			
191	NM_152833.2	C9ORF69	chromosome 9 open reading frame 69			
192	NM_153201.1	HSPA8	heat shock 70kDa protein 8			
193	NM_153214.1	FBLN7	fibulin 7			
194	NM_153332.3	ERI1	exoribonuclease 1			
195 196	NM_153609.2 NM_173343.1	TMPRSS6 IL1R2	transmembrane protease, serine 6 interleukin 1 receptor, type II			
196	NM_173343.1 NM_173798.2	ZCCHC12	zinc finger, CCHC domain containing 12			
197	NM_173799.2	TIGIT	T cell immunoreceptor with Ig and ITIM domains			
198	NM 173815.3	FLJ37464	hypothetical protein FLJ37464			
200	NM 175852.3	TXLNA	taxilin alpha			
200	NM 178562.2	TSPAN33	tetraspanin 33			
202	NM 178834.2	LAYN	layilin			

203	NM_181652.1	PRDX5	peroxiredoxin 5			
204	NM_183079.1	PRNP	prion protein (p27-30)			
205	NM_194071.2	CREB3L2	cAMP responsive element binding protein 3-like 2			
206	NM_198828.1	LOC375449	similar to microtubule associated testis specific			
			serine/threonine protein kinase			
207	NR_001298.1	HLA-DRB6	major histocompatibility complex, class II, DR beta 6			
			(pseudogene)			
208	NR_002733.1	DGCR5	DiGeorge syndrome critical region gene 5 (non-protein			
			coding)			
209	NR_004845.1	LOC644936	actin, beta pseudogene			
210	NR_024392.1	HSPBL2	heat shock 27kDa protein-like 2 pseudogene			
211	XM_925989.1	LOC642489	similar to FK506-binding protein 1A			
212	XM_926168.1	LOC643025	similar to Probable phosphoglycerate mutase 4			
213	XM_929420.1	LOC653377	similar to family with sequence similarity 36, member A			
214	XM_939115.1	MGC4677	hypothetical protein MGC4677			
215	XM_939906.1	LOC650815	similar to T-cell receptor alpha chain V region CTL-L17			
			precursor			
216	XR_016557.2	LOC391075	misc_RNA			

Table S2

List of the pathways significantly (p < 0.05) enriched among the 216 genes upregulated in Treg CT OX40+ (www.reactome.org).

Pathway name	Entities found	Entities total	Entities ratio	Entities pValue
Interleukin-4 and 13 signaling	18	212	0.16	2.08E-7
Cytokine Signaling in Immune System	44	1006	0.075	2.45E-7
Signaling by Interleukins	31	688	0.051	1.01E-5
Fibronectin matrix formation	3	7	0.001	3.58E-4
Interferon Signaling	15	292	0.022	5.89E-4
Immune System	71	2616	0.195	9.66E-4
Transferrin endocytosis and recycling	5	39	0.003	1.01E-3
Neutrophil degranulation	20	480	0.036	1.05E-3
Glycolysis	6	63	0.005	1.48E-3
MHC class II antigen presentation	9	142	0.011	1.86E-3
Insulin receptor recycling	4	28	0.002	2.2E-3
Formation of the cornified envelope	8	130	0.01	3.9E-3
Glucose metabolism	8	131	0.01	4.08E-3
RHO GTPases activate IQGAPs	4	35	0.003	4.85E-3
Iron uptake and transport	6	83	0.006	5.64E-3
Activation of NOXA and translocation to	2	6	0	6.08E-3
mitochondria				
Interferon alpha/beta signaling	8	141	0.011	6.26E-3
BH3-only proteins associate with and inactivate	2	8	0.001	1.05E-2
anti-apoptotic BCL-2 members				
Cell surface interactions at the vascular wall	11	256	0.019	1.11E-2
Semaphorin interactions	5	73	0.005	1.38E-2
Intrinsic pathways for apoptosis	4	49	0.004	1.52E-2
Nef Mediated CD4 Down-regulation	2	10	0.001	1.61E-2
Aflatoxin activation and detoxification	4	50	0.004	1.62E-2
Sema4D induced cell migration and growth-cone	3	28	0.002	1.71E-2
collapse		• •		
Regulation of IFNA signaling	3	28	0.002	1.71E-2
The role of Nef in HIV-1 replication and disease pathogenesis	3	29	0.002	1.87E-2
TNFa binds their physiological receptors	3	30	0.002	2.05E-2
Inteferon gamma signaling	8	186	0.002	2.03E-2 2.11E-2
The role of GTSE1 in G2/M progression after G2	5	82	0.006	2.16E-2
checkpoint	5	02	0.000	2.101-2
AUF (hnRNP D0) binds and destabilizes mRNA	4	56	0.004	2.34E-2
Sema4D in semaphorin signaling	3	33	0.002	2.61E-2
Interleukin-12 family signaling	2	13	0.001	2.62E-2
Translocation of GLUT4 to the plasma	5	87	0.006	2.69E-2
membrane	5	07	0.000	2.09112
Activation of BH3-only proteins	3	36	0.003	3.26E-2
Regulation of IFNG signaling	2	16	0.001	3.82E-2
COPI-mediated anterograde transport	5	100	0.007	4.45E-2
Activation of gene expression by SREBF (SREBP)	4	70	0.005	4.66E-2
Translocation of ZAP-70 to Immunological synapse	3	42	0.003	4.76E-2